Compass Therapeutics, Inc.
No enriched coverage for $CMPX in the last 7 days.
No SEC Form 4 filings for $CMPX in the last 30 days.
This article provides access to a DEFA14A filing by Compass Therapeutics. These filings are preliminary proxy statements that include important information for shareholders prior to a definitive proxy statement.
Compass Therapeutics has released its full 2025 financial results, highlighting significant progress in its clinical-stage pipeline. The company reported $209 million in cash and marketable securities, providing a runway into 2028. Key updates include reaching the event threshold for its tovecimig study in biliary tract cancer, expanding cohorts for CTX-8371 in TNBC and NSCLC, and FDA clearance for CTX-10726, with Phase 1 studies commencing.
Compass Therapeutics' stock (CMPX) has reached a new 52-week high of $6.51 USD, marking a significant surge of 98.76% over the past year. The company, with a market capitalization of $1.14 billion, has seen substantial growth due to strategic advancements and strong investor confidence. Analysts maintain bullish ratings, projecting further upside potential for the biotech firm.
